γ-Cyclodextrin nanoparticle eye drops with dorzolamide: effect on intraocular pressure in man.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsGudmundsdottir, Birna S
Asgrimsdottir, Gudrun M
Gottfredsdottir, Maria S
Hardarson, Sveinn H
Kurkov, Sergey V
MetadataShow full item record
CitationJ Ocul Pharmacol Ther. 2014, 30 (1):35-41
AbstractTo test a new drug delivery platform with dorzolamide γ-cyclodextrin (γCD) nanoparticle eye drops for intraocular pressure (IOP) control and safety and compare with Trusopt.(®)
Self-aggregating γCD nanoparticle eye drops containing 3% dorzolamide were given once a day (QD) and compared with Trusopt given three times a day (TID) in a prospective randomized single masked crossover trial over 24 h. Seventeen subjects with IOP over 18 mmHg were recruited. IOP was measured with an Icare Tonometer Pro.(®) Results: There was no statistically significant difference in the IOP lowering effect of dorzolamide nanoparticle eye drops QD and Trusopt TID. At peak (4 h), the IOP reduction from baseline was 3.8±2.6 mmHg (18%, P<0.05) in the nanoparticle eye drop group and 3.1±3.7 mmHg in the Trusopt group (14%, P<0.05, P=0.97 between groups). At trough (24 h), the IOP reduction was 1.4±2.8 mmHg (6%, P>0.05) in nanoparticle eye drop group and 1.5±2.0 mmHg (7%, P>0.05) in the Trusopt group (P=0.23 between groups). Burning sensation measured on the visual analogue scale (1-100) was less from the nanoparticle eye drops (12±15) than from the Trusopt (37±30), (P=0.0038). Visual acuity and conjunctival hyperemia did not differ between the two groups.
Dorzolamide cyclodextrin nanoparticle eye drops QD lower IOP and the effect seems comparable to Trusopt given TID. The nanoparticle eye drops are well tolerated and seem to have a better safety profile than Trusopt.
DescriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the page
RightsArchived with thanks to Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
- Dorzolamide cyclodextrin nanoparticle suspension eye drops and Trusopt in rabbit.
- Authors: Jóhannesson G, Moya-Ortega MD, Asgrímsdóttir GM, Agnarsson BA, Lund SH, Loftsson T, Stefánsson E
- Issue date: 2014 Aug
- Pharmacodynamic equivalence study of two preparations of eye drops containing dorzolamide and timolol in healthy volunteers.
- Authors: Gatchev E, Petrov A, Kolev E, Hristova R, Demircheva I, Koytchev R, Richter W, Tegel F, Thyroff-Friesinger U
- Issue date: 2011
- Methazolamide 1% in cyclodextrin solution lowers IOP in human ocular hypertension.
- Authors: Gudmundsdóttir E, Stefánsson E, Bjarnadóttir G, Sigurjónsdóttir JF, Gudmundsdóttir G, Masson M, Loftsson T
- Issue date: 2000 Oct
- Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
- Authors: Whitson JT, Henry C, Hughes B, Lee DA, Terry S, Fechtner RD
- Issue date: 2004 Apr
- Kinetics of γ-cyclodextrin nanoparticle suspension eye drops in tear fluid.
- Authors: Jóhannesson G, Moya-Ortega MD, Ásgrímsdóttir GM, Lund SH, Thorsteinsdóttir M, Loftsson T, Stefánsson E
- Issue date: 2014 Sep